W

elcome to the corner office! Each month, we’ll turn to a new panel of biopharma executives for insights about leadership and management — and tips for thriving in a roller-coaster industry. To share your views in future columns, please fill out this short form. To suggest questions for our panelists, email STAT Plus Editor Liz Cooney. This month, we asked:

How do you coach your team to respond to setbacks?

Emily Leproust, CEO of Twist Bioscience, San Francisco, Calif.: At Twist Bioscience, one of our guiding principles is grit, which we define as passionate drive and fierce determination. By demonstrating grit, we have built a culture of innovation and excellence, which, by necessity requires experimentation. Experimentation results in success but also in setbacks, which we must allow for in a way that is safe and encourages risk-taking.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nice words, but 1) your coaching will have to distract your team from fear based furiously updating their resumes and 2) everyone will be searching for scapegoats when, on their upcoming interviews they are asked why your company’s drug failed. Since I was in clinical development it was NEVER the fault of my excellent protocol designs; better to crucify the nameless, faceless statisticians who blew the sample size calculations, or the bozos in regulatory affairs who gave you bad advice.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.